Boehringer, Lilly face off in MASH at EASL June 10, 2024 AutoBot News 0 Drugs from Eli Lilly and Boehringer Ingelheim grabbed the spotlight at the EASL congress on liver diseases, both showing promising results in metabolic dysfunction-associated steatohepatitis (MASH).